Join the Cervical Cancer group to help and get support from people like you.
Cervical Cancer News (Page 3)
Related terms: Cancer, Cervix
Sample-to-Answer, Point-of-Care HPV DNA Test Feasible
TUESDAY, June 27, 2023 – A sample-to-answer, point-of-care human papillomavirus (HPV) DNA test is feasible and can be performed by minimally trained personnel, according to a study published online...
American Society of Clinical Oncology, June 2-6
The annual meeting of the American Society of Clinical Oncology was held from June 2 to 6 in Chicago and attracted more than 34,000 participants from around the world, including clinicians,...
Money Troubles Can Delay Cancer Diagnoses, Putting Survival in Jeopardy
TUESDAY, June 6, 2023 – Money woes have long been linked to worse health care. Now, a new study finds financially strapped patients often put off cancer screenings – only to learn they have the...
ASCO: Adding Pembrolizumab to Chemo Improves Survival in Cervical Cancer
THURSDAY, June 1, 2023 – For women with persistent, recurrent, or metastatic cervical cancer, adding pembrolizumab to chemotherapy, with or without bevacizumab, is associated with improved overall...
FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin
Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
BRIDGEWATER, N.J.--(BUSINESS WIRE) April 13, 2022 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
KENILWORTH, N.J.--(BUSINESS WIRE) October 13, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Grants Accelerated Approval for Tivdak (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE) September 20, 2021-- Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA)...
FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin
Friday, June 28, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved Zirabev (bevacizumab-bvzr), a biosimilar to...
FDA Approves Expanded Use of Gardasil 9 to Include Individuals 27 Through 45 Years Old
October 5, 2018 – The U.S. Food and Drug Administration today approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use...
FDA Approves Keytruda (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1
KENILWORTH, N.J.--(BUSINESS WIRE) June 12, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
September 14, 2017 – The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is...
FDA Approves Expanded Age Indication for Gardasil 9 in Males
KENILWORTH, N.J.--(BUSINESS WIRE) December 15, 2015 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved...
FDA Approves Gardasil 9 for Prevention of Certain Cancers Caused by Five Additional Types of HPV
December 10, 2014 – The U.S. Food and Drug Administration today approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types...
FDA Approves Avastin for Metastatic Cervical Cancer
August 14, 2014 – The U.S. Food and Drug Administration today approved a new use for Avastin (bevacizumab) to treat patients with persistent, recurrent or late-stage (metastatic) cervical cancer. ...
Ask a question
To post your own question to this support group, sign in or create an account.